Clovis Oncology slides on disappointing results
08/08/2022 14:11
** Shares of Clovis Oncology Inc CLVS.O fall ~16% to $1.40
in premarket trading
** Co reports Q2 revenue of sole product, second-line
ovarian cancer therapy Rubraca, at $32.1 mln, missing average
estimates of 37 mln - Refinitiv data urn:newsml:reuters.com:*:nBw2ywR3da
** Adds increase in ovarian cancer diagnoses to pre-COVID
levels would only benefit first-line therapies, and will likely
not impact second-line therapies such as Rubraca for several
quarters
** Up to Friday's close, stock down ~39%
(Reporting by Raghav Mahobe)
((Raghav.Mahobe@thomsonreuters.com;))
Recent news on Clovis Oncology
See all newsBrief: Clovis Oncology Inc - On April 5, 2023, Entered Into Asset Purchase Agreement With Pharma& To Sell Product Business For Upfront Payment Of $70 Million
Brief: Clovis Oncology Enters Into Financing Agreement
Brief: Clovis Oncology Inc Received Written Notice From Nasdaq That Company's Common Stock Will Be Delisted From Nasdaq
U.S. STOCKS ON THE MOVE-Nike, Faraday Future, PBF Energy
U.S. STOCKS ON THE MOVE-Natural gas, Box Inc, Weber